Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670

Diabetes Care

Volumn 37, Issue 10, 2014, Pages e218-

  Chaudhuri, Ajay ^a   Kuhadiya, Nitesh ^a   Ghanim, Husam ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; LIRAGLUTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN TYROSINE PHOSPHATASE 1B; SUPPRESSOR OF CYTOKINE SIGNALING 3; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; NOTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 1; FEMALE; MALE;

DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PEPTIDES; VENOMS;

EID: 84908164209     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1052     Document Type: Note

References (5)

1. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014;37: 666-670.
2. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77-84.
3. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013;19:963-967.
4. Viswanathan P, Chaudhuri A, Bhatia R, Al- Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13:444-450.
5. Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012;97: 198-207.